Market Overview

UPDATE: BMO Capital Markets Downgrades Bristol-Myers Squibb to Market Perform, Lowers PT

Share:
Related BMY
Bristol-Myers Squibb to Host Investor Teleconference to Discuss World Conference on Lung Cancer (WCLC) Highlights
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Non-Squamous Non-Small Cell Lung Cancer Patients
Bristol-Myers' (BMY) Opdivo Gets Priority Review, Shares Up (Zacks)

In a report published Monday, BMO Capital Markets downgraded its rating on Bristol-Myers Squibb (NYSE: BMY) from Outperform to Market Perform, and slightly lowered its price target from $38.00 to $37.00.

BMO Capital noted, “With strong results from the Phase-2 ELECTRON trial (100% SVR), Gilead has solidified its lead in the Hep-C market. The data significantly lowers the potential for BMS' Hep-C portfolio, and sets a high bar for the rest of the competitors. Similarly, Merck reported solid results for its anti-PD-1 cancer immunotherapy, MK-3475, in advanced melanoma. MK-3475 appears to be on par with BMS'558, if not better; however, we have yet to see longer term data including the durability of responses. As a result of a number of pipeline setbacks this year and competitive developments, we have now adopted a more cautious view on BMS' pipeline. Although we still expect Eliquis to get a best in class label and get approved ahead of its 3/17/13 PDUFA, much of that is now expected by the market and its launch could be choppy.”

Bristol-Myers Squibb closed on Friday at $32.23.

Latest Ratings for BMY

DateFirmActionFromTo
Aug 2015JefferiesMaintainsHold
Aug 2015Piper JaffrayUpgradesUnderN
Aug 2015JefferiesMaintainsHold

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Downgrades Analyst Ratings

 

Related Articles (BMY)

View Comments and Join the Discussion!

Get Benzinga's Newsletters